Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

TRIM28 promotes HIV-1 latency by SUMOylating CDK9 and inhibiting P-TEFb.

Ma, Xiancai; Yang, Tao; Luo, Yuewen; Wu, Liyang; Jiang, Yawen; Song, Zheng; Pan, Ting; Liu, Bingfeng; Liu, Guangyan; Liu, Jun; Yu, Fei; He, Zhangping; Zhang, Wanying; Yang, Jinyu; Liang, Liting; Guan, Yuanjun; Zhang, Xu; Li, Linghua; Cai, Weiping; Tang, Xiaoping; Gao, Song; Deng, Kai; Zhang, Hui.
Elife; 82019 01 17.
Artigo em Inglês | MEDLINE | ID: mdl-30652970
Comprehensively elucidating the molecular mechanisms of human immunodeficiency virus type 1 (HIV-1) latency is a priority to achieve a functional cure. As current 'shock' agents failed to efficiently reactivate the latent reservoir, it is important to discover new targets for developing more efficient latency-reversing agents (LRAs). Here, we found that TRIM28 potently suppresses HIV-1 expression by utilizing both SUMO E3 ligase activity and epigenetic adaptor function. Through global site-specific SUMO-MS study and serial SUMOylation assays, we identified that P-TEFb catalytic subunit CDK9 is significantly SUMOylated by TRIM28 with SUMO4. The Lys44, Lys56 and Lys68 residues on CDK9 are SUMOylated by TRIM28, which inhibits CDK9 kinase activity or prevents P-TEFb assembly by directly blocking the interaction between CDK9 and Cyclin T1, subsequently inhibits viral transcription and contributes to HIV-1 latency. The manipulation of TRIM28 and its consequent SUMOylation pathway could be the target for developing LRAs.
Selo DaSilva